Q1 Revenue Up 20%, But Net Loss Widens 28% Amid Accelerated Cash Burn; CFO Adopts Stock Sale Plan
PRCT sits 24% above its 52-week low of $19.35 on elevated volume (2.4× avg).
Summary
PROCEPT BioRobotics reported 20% Q1 revenue growth and improved gross margins, but net loss widened 28% and operating cash burn more than doubled; CFO adopted a pre-planned stock sale.
Key Events · Earnings and Guidance · PRCT
-
Strong Revenue Growth Continues
Revenue increased by 20% year-over-year to $83.1 million for the three months ended March 31, 2026, driven by higher system sales, handpieces, and service contracts.
-
Gross Margin Improvement
Gross margin slightly improved to 65% in Q1 2026, up from 64% in Q1 2025, primarily due to increased unit sales spreading fixed manufacturing overhead costs.
-
Net Loss Widens Significantly
Net loss increased by 28% to $31.6 million in Q1 2026, compared to $24.7 million in the prior-year period, as operating expenses grew faster than revenue.
-
Accelerated Operating Cash Burn
Net cash used in operating activities more than doubled to $38.1 million in Q1 2026, compared to $17.0 million in Q1 2025, reflecting increased commercialization and development investments.
Analysis · PRCT · Industrial Applications And Services
PROCEPT BioRobotics' Q1 2026 report confirms robust revenue growth and improved gross margins, aligning with prior disclosures. However, the detailed financials reveal a significant widening of the net loss and a more than doubling of cash used in operating activities, indicating substantial investments in growth initiatives. While the company maintains a strong cash position and projects over 12 months of liquidity, the accelerated cash burn rate is a critical factor for investors assessing the path to profitability and potential future capital requirements. The CFO's adoption of a Rule 10b5-1 plan to sell shares, though pre-planned and modest, adds a slight negative signal regarding insider sentiment.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 29.6% of the 2932 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRCT was trading at $23.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $19.35 to $66.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.